Eterna Therapeutics (ERNA) Revenue & Revenue Breakdown
Eterna Therapeutics Revenue Highlights
Latest Revenue (Y)
$68.00K
Latest Revenue (Q)
$487.00K
Eterna Therapeutics Revenue by Period
Eterna Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $68.00K | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $19.81M | - |
Eterna Therapeutics generated $68.00K in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Eterna Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $487.00K | 936.17% |
| 2024-06-30 | $47.00K | - |
| 2024-03-31 | $47.00K | 176.47% |
| 2023-12-31 | $17.00K | -66.67% |
| 2023-09-30 | $51.00K | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-09-30 | $4.58M | -12.36% |
| 2019-06-30 | $5.23M | 8.15% |
| 2019-03-31 | $4.83M | -19.52% |
| 2018-09-30 | $6.00M | 6.25% |
| 2018-06-30 | $5.65M | -1.91% |
| 2018-03-31 | $5.76M | 10.83% |
| 2017-09-30 | $5.20M | -6.33% |
| 2017-06-30 | $5.55M | 6.08% |
| 2017-03-31 | $5.23M | -3.89% |
| 2016-09-30 | $5.44M | 0.67% |
| 2016-06-30 | $5.41M | -1.37% |
| 2016-03-31 | $5.48M | -9.82% |
| 2015-09-30 | $6.08M | -1.84% |
| 2015-06-30 | $6.19M | 8.16% |
| 2015-03-31 | $5.73M | -4.65% |
| 2014-09-30 | $6.00M | - |
Eterna Therapeutics generated $487.00K in revenue during Q3 2024, up 936.17% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Eterna Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
| RCUS | Arcus Biosciences | $117.00M | $48.00M |
| RLAY | Relay Therapeutics | $25.55M | - |
| TCRX | TScan Therapeutics | $21.05M | - |
| ITOS | iTeos Therapeutics | $12.60M | $35.00M |
| UNCY | Unicycive Therapeutics | $675.00K | - |
| PALI | Palisade Bio | $250.00K | - |
| ERNA | Eterna Therapeutics | $68.00K | $487.00K |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| XFOR | X4 Pharmaceuticals | - | $560.00K |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ZURA | Zura Bio | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| REVB | Revelation Biosciences | - | - |
| ANNX | Annexon | - | - |
| PHIO | Phio Pharmaceuticals | - | - |
| ZVSA | ZyVersa Therapeutics | - | - |
| IMMX | Immix Biopharma | - | - |
| RNAZ | TransCode Therapeutics | - | - |